A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) who Have not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306)

  • Arulananda, Surein (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date28/02/24 → 27/02/29